Helminth therapy (worms) for induction of remission in inflammatory bowel disease

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 1, 2014, Pages

  Garg, Sushil K ^a   Croft, Ashley M ^b   Bager, Peter ^c  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b MINISTRY OF DEFENCE   (United Kingdom)

^c STATENS SERUM INSTITUT   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL EFFECTIVENESS; CLINICAL OUTCOME; DISEASE ACTIVITY; DYSGEUSIA; GENERAL CONDITION IMPROVEMENT; HUMAN; INFLAMMATORY BOWEL DISEASE; PATIENT SAFETY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; SCORING SYSTEM; SYSTEMATIC REVIEW; THERAPY WITH HELMINTHS; TRICHURIS SUIS; ULCERATIVE COLITIS; ANIMAL; CROHN DISEASE; META ANALYSIS; METHODOLOGY; OOCYTE; TRANSPLANTATION; TRICHURIS;

ANIMALS; COLITIS, ULCERATIVE; CROHN DISEASE; HUMANS; INFLAMMATORY BOWEL DISEASES; OVUM; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMISSION INDUCTION; THERAPY WITH HELMINTHS; TRICHURIS;

EID: 84903817656     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD009400.pub2     Document Type: Review

References (60)

1. Sandborn WJ, Elliott DE, Weinstock J, Summers RW, Landry-Wheeler A, Silver N, et al. Randomised clinical trial: the safety and tolerability of Trichuris suis ova in patients with Crohn's disease. Alimentary Pharmacology and Therapeutics 2013;38(3):255-63.
2. Summers RW, Elliott DE, Urban JF Jr, Thompson RA, Weinstock JV. Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial. Gastroenterology 2005;128(4):825-32.
3. Croese J, O'neil J, Masson J, Cooke S, Melrose W, Pritchard D, et al. A proof of concept study establishing Necator americanus in Crohn's patients and reservoir donors. Gut 2006;55(1):136-7.
4. Summers RW, Elliott DE, Qadir K, Urban JFJ, Thompson R, Weinstock JV. Trichuris suis seems to be safe and possibly effective in the treatment of inflammatory bowel disease. American Journal of Gastroenterology 2003;98(9):2034-41.
5. Summers RW, Elliott DE, Urban JF Jr, Thompson R, Weinstock JV. Trichuris suis therapy in Crohn's disease. Gut 2005;54(1):87-90.
6. NCT01279577 Trichuris suis ova (TSO) suspension versus placebo in active Crohn's disease (TRUST-2). http://clinicaltrials.gov/ct2/show/NCT01279577 accessed 13 July 2013.
7. NCT01434693 Safety and tolerability of single doses oral CNDO 201 Trichuris suis ova in patients with Crohn's disease. http://clinicaltrials.gov/ct2/show/NCT01434693 accessed 13 July 2013.
8. Akobeng AK, Zachos M. Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease. Cochrane Database of Systematic Reviews 2003, Issue 4. [DOI: 10.1002/14651858.CD003574.pub2]
9. Bager P, Arnved J, Rønborg S, Wohlfahrt J, Poulsen LK, Westergaard T, et al. Trichuris suis ova therapy for allergic rhinitis: a randomized, double-blind, placebo-controlled clinical trial. Journal of Allergy and Clinical Immunology 2010;125(1):123-30.
10. Bager P, Kapel C, Roepstorff A, Thmaborg S, Arnved J, Rønborg S, et al. Symptoms after ingestion of pig whipworm Trichuris suis eggs in a randomized placebo-controlled double-blind clinical trial. PLoS One 2011;8(6):1-11.
11. Behm BW, Bickston SJ. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease. Cochrane Database of Systematic Reviews 2008, Issue 1. [DOI: 10.1002/14651858.CD006893]
12. Benchimol EI, Seow CH, Steinhart AH, Griffiths AM. Traditional corticosteroids for induction of remission in Crohn's disease. Cochrane Database of Systematic Reviews 2008, Issue 2. [DOI: 10.1002/14651858.CD006792.pub2]
13. Blount D, Hooi D, Feary J, Venn A, Telford G, Brown A, et al. Immunologic profiles of persons recruited for a randomized, placebo-controlled clinical trial of hookworm infection. American Journal of Tropical Medicine and Hygiene 2009;81(5):911-6.
14. Borkow G, Leng Q, Weisman Z, Stein M, Galai N, Kalinkovich A, et al. Chronic immune activation associated with intestinal helminth infections results in impaired signal transduction and anergy. Journal of Clinical Investigation 2000;106(8):1053-60.
15. Brant R, Sutherland L, Hilsden R. Examining the minimum important difference. Statistics in Medicine 1999;18(19):2593-603.
16. ChandeN, MacDonald JK, McDonald JWD. Methotrexate for induction of remission in ulcerative colitis. Cochrane Database of Systematic Reviews 2007, Issue 4. [DOI: 10.1002/14651858.CD006618.pub2]
17. Chande N, Tsoulis DJ, MacDonald JK. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database of Systematic Reviews 2013, Issue 4. [DOI: 10.1002/14651858.CD000545.pub4]
18. Croft AM, Bager P, Kumar S. Helminth therapy (worms) for allergic rhinitis. Cochrane Database of Systematic Reviews 2012, Issue 4. [DOI: 10.1002/14651858.CD009238.pub2]
19. Daveson JA, Jones DM, Gaze S, McSorley H, Clouston A, Pascoe A, et al. Effect of hookworm infection on wheat challenge in celiac disease - a randomised double-blind placebo controlled trial. PLoS One 2011;6(3):1-9.
20. Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
21. Dwinell MB, Bass P, Schaefer DM, Oaks JA. Tapeworm infection decreases intestinal transit and enteric aerobic bacterial populations. American Journal of Physiology 1997;273(2 Pt 1):G480-5.
22. Elliott DE, Urban JF Jr, Argo CK, Weinstock JV. Does the failure to acquire helminthic parasites predispose to Crohn's disease?. FASEB Journal 2000;14(12):1848-55.
23. Elliott DE, Li J, Blum A, Metwali A, Qadir K, Urban JF Jr, et al. Exposure to schistosome eggs protects mice from TNBS-induced colitis. American Journal of Physiology. Gastrointestinal and Liver Physiology 2003;284(3):G385-91.
24. Elliott DE, Summers RW, Weinstock JV. Helminths as governors of immune-mediated inflammation. International Journal for Parasitology 2007;37(5):457-64.
25. Elliott DE, Metwali A, Leung J, Setiawan T, Blum AM, Ince MN, et al. Colonization with Heligmosomoides polygyrus suppresses mucosal IL-17 production. Journal of Immunology 2008;181(4):2414-9.
26. Feagan BG, MacDonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database of Systematic Reviews 2012, Issue 10. [DOI: 10.1002/14651858.CD000543.pub3]
27. Feagan BG, MacDonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database of Systematic Reviews 2012, Issue 10. [DOI: 10.1002/14651858.CD000544.pub3]
28. Feary J, Venn A, Brown A, Hooi D, Falcone FH, Mortimer K, et al. Safety of hookworm infection in individuals with measurable airway responsiveness: a randomized placebo-controlled feasibility study. Clinical and Experimental Allergy 2009;39(7):1060-8.
29. Feary JR, Venn AJ, Mortimer K, Brown AP, Hooi D, Falcone FH, et al. Experimental hookworm infection: a randomized placebo-controlled trial in asthma. Clinical and Experimental Allergy 2009;40(2):299-306.
30. Finch RG, Irving WL, Moss P, AndersonJ Infectious diseases, tropical medicine and sexually transmitted infection. In: Kumar P, Clark M editor(s). Kumar and Clark's Clinical Medicine. 7th Edition. London: Saunders, 2009.
31. Hang L, Setiawan T, Blum AM, Urban J, Stoyanoff K, Arihiro S, et al. Heligmosomoides polygyrus infection can inhibit colitis through direct interaction with innate immunity. Journal of Immunology 2010;185(6):3184-9.
32. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
33. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
34. Higgins JPT, Deeks JJ, Altman DG (editors). Chapter 16: Special topics in statistics. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
35. Hunter MM, Wang A, Hirota CL, McKay DM. Neutralizing anti-IL-10 antibody blocks the protective effect of tapeworm infection in a murine model of chemically induced colitis. Journal of Immunology 2005;174(11):7368-75.
36. Ince MN, Elliott DE, Setiawan T, Metwali A, Blum A, Chen HL, et al. Role of T cell TGF-beta signaling in intestinal cytokine responses and helminthic immune modulation. European Journal of Immunology 2009;39(7):1870-8.
37. Kitagaki K, Businga TR, Racila D, Elliott DE, Weinstock JV, Kline JN. Intestinal helminths protect in a murine model of asthma. Journal of Immunology 2006;177(3):1628-35.
38. Lawson MM, Thomas AG, Akobeng AK. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database of Systematic Reviews 2006, Issue 3. [DOI: 10.1002/14651858.CD005112.pub2]
39. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
40. Lim WC, Hanauer S. Aminosalicylates for induction of remission or response in Crohn's disease. Cochrane Database of Systematic Reviews 2010, Issue 12. [DOI: 10.1002/14651858.CD008870]
41. Mangan NE, Fallon RE, Smith P, van Rooijen N, McKenzie AN, Fallon PG. Helminth infection protects mice from anaphylaxis via IL-10-producing B cells. Journal of Immunology 2004;173(10):6346-56.
42. Marshall JK, Thabane M, Steinhart AH, Newman JR, Anand A, Irvine EJ. Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database of Systematic Reviews 2010, Issue 1. [DOI: 10.1002/14651858.CD004115.pub2]
43. McDonald JW, Tsoulis DJ, MacDonald JK, Feagan BG. Methotrexate for induction of remission in refractory Crohn's disease. Cochrane Database of Systematic Reviews 2012, Issue 12. [DOI: 10.1002/14651858.CD003459.pub3]
44. McKay DM, Halton DW, McCaigue MD, Johnston CF, Fairweather I, Shaw C. Hymenolepis diminuta: intestinal goblet cell response to infection in male C57 mice. Experimental Parasitology 1990;71(1):9-20.
45. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Medicine 2009;6(7):1-6.
46. Olano JP, Weller PF, Guerrant RL, Walker DH. Principles and general considerations. In: Guerrant RL, Walker DH, Weller PF editor(s). Tropical Infectious Diseases - Principles, Pathogens and Practice. 2nd Edition. London: Churchill Livingstone, 2006.
47. Podolsky DK. Inflammatory bowel disease. New England Journal of Medicine 2002;347(6):417-29.
48. Prefontaine E, Sutherland LR, MacDonald JK, Cepoiu M. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. Cochrane Database of Systematic Reviews 2009, Issue 1. [DOI: 10.1002/14651858.CD000067.pub2]
49. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
50. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine 2005;353(23):2462-76.
51. Sabin EA, Araujo MI, Carvalho EM, Pearce EJ. Impairment of tetanus toxoid-specific Th1-like immune responses in humans infected with Schistosoma mansoni. Journal of Infectious Diseases 1996;173(1):269-72.
52. Schnoeller C, Rausch S, Pillai S, Avagyan A, Wittig BM, Loddenkemper C, et al. A helminth immunomodulator reduces allergic and inflammatory response by induction of IL-10-producing macrophages. Journal of Immunology 2008;180(6):4265-72.
53. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
54. Seow CH, Benchimol EI, Griffiths AM, Otley AR, Steinhart AH. Budesonide for induction of remission in Crohn's disease. Cochrane Database of Systematic Reviews 2008, Issue 3. [DOI: 10.1002/14651858.CD000296.pub3]
55. Smith P, Mangan NE, Walsh CM, Fallon RE, McKenzie AN, van Rooijen N, et al. Infection with a helminth parasite prevents experimental colitis via a macrophage-mediated mechanism. Journal of Immunology 2007;178(7):4557-66.
56. Strickland GT. Helminthic infections. In: Strickland GT editor(s). Hunter's Tropical Medicine and Emerging Infectious Diseases. 9th Edition. Philadelphia, Pa: Saunders, 1999.
57. Timmer A, McDonald JWD, Tsoulis DJ, MacDonald JK. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database of Systematic Reviews 2012, Issue 9. [DOI: 10.1002/14651858.CD000478.pub3]
58. Wammes LJ, Hamid F, Wiria AE, de Gier B, Sartono E, Maizels RM, et al. Regulatory T cells in human geohelminth infection suppress immune responses to BCG and Plasmodium falciparum. European Journal of Immunology 2010;40(2):437-42.
59. Wang SL, Wang ZR, Yang CQ. Meta-analysis of broad-spectrum antibiotic therapy in patients with active inflammatory bowel disease. Experimental and Therapeutic Medicine 2012;4(6):1051-6.
60. Weller PF, Nutman TB. Intestinal nematodes. In: Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson JL, et al. editor(s). Harrison's Principles of Internal Medicine. 17th Edition. New York: McGraw-Hill, 2008.